• Home
  • >
  • Marksans Pharma Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/marksans-pharma-ltd.png Logo

Marksans Pharma Ltd Financial Statement

Marksans Pharma Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Dec 2023Sep 2023Jun 2023
Revenue242.69220.6214.66
Operating Expense199.39167.37155.28
Net Profit25.2931.2944.19
Net Profit Margin10.4214.1820.59
Earning Per Share0.560.690.98
EBIDTA43.7551.756.68
Effective Tax Rate22.5421.9412.65

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Marksans Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual1,852.141,490.841,376.18
Operating Expenses Annual1,512.821,231.961,036.57
Operating Profit Annual398.63300.73346.3
Interest Annual9.138.457.99
Depreciation41.3740.6919.5
Net Profit Annual266.31184.57238.54
Tax Annual72.3360.763.63

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Marksans Pharma Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning206.41212.1893.73
Cash Flow from Operations237.4199.26178.74
Cash Flow from Investing-259.21-41.69-44.9
Cash Flow from Financing197.8379.51-15.29
Cash Flow at the End382.44349.27212.29

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Marksans Pharma Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)21.5220.1725.16
PBIT Margin (%)18.7217.1722.54
PBT Margin (%)12.9212.5716.07
Net PROFIT Margin (%)15.715.816.41
Return On Networth / Equity (%)1817.8931.34
Return On Networth /Employed(%)21.7722.8338.77
Return On Assets (%)18.0620.6927.73
Total Debt / Equity(X)0.010.020.02
Asset Turnover Ratio (%)1.151.311.69

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Marksans Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual488.93430.19315.44
Total Current Assets Annual1,675.31,201.2902.82
Non Current Assets Annual515.09438.9326
Total Shareholders Funds Annual1,745.161,202.27886.5
Total Assets Annual2,190.391,640.11,228.82

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Marksans Pharma Ltd Earning Calls
Dec 2023
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Marksans Pharma Ltd has a market capitalization of 3,194.35 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Marksans Pharma Ltd is debt-free with a debt-to-equity ratio of 0.07.

In FY 2023, Marksans Pharma Ltd recorded a total revenue of approximately 1,852.14 Cr marking a significant milestone in the company's financial performance.

Marksans Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and 0.1% annually, respectively..

Marksans Pharma Ltd's current PE ratio is 11.99.

Marksans Pharma Ltd's ROCE averaged 23.9% from the FY ending March 2021 to 2023, with a median of 19.5%. It peaked at 33.5% in March 2021, reflecting strong capital efficiency over the period..

Marksans Pharma Ltd's latest EBIT is Rs. 346.78 Cr, surpassing the average EBIT of Rs. 304.3 Cr over the 5 years..